Affiliation:
1. Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City 04510, Mexico
2. Departamento de Microscopía Electrónica, Instituto Nacional de Cancerología, Secretaría de Salud, Mexico City 14080, Mexico
Abstract
The protein p32 (C1QBP) is a multifunctional and multicompartmental homotrimer that is overexpressed in many cancer types, including colon cancer. High expression levels of C1QBP are negatively correlated with the survival of patients. Previously, we demonstrated that C1QBP is an essential promoter of migration, chemoresistance, clonogenic, and tumorigenic capacity in colon cancer cells. However, the mechanisms underlying these functions and the effects of specific C1QBP protein inhibitors remain unexplored. Here, we show that the specific pharmacological inhibition of C1QBP with the small molecule M36 significantly decreased the viability rate, clonogenic capacity, and proliferation rate of different colon cancer cell lines in a dose-dependent manner. The effects of the inhibitor of C1QBP were cytostatic and non-cytotoxic, inducing a decreased activation rate of critical pro-malignant and mitogenic cellular pathways such as Akt-mTOR and MAPK in RKO colon cancer cells. Additionally, treatment with M36 significantly affected the mitochondrial integrity and dynamics of malignant cells, indicating that p32/C1QBP plays an essential role in maintaining mitochondrial homeostasis. Altogether, our results reinforce that C1QBP is an important oncogene target and that M36 may be a promising therapeutic drug for the treatment of colon cancer.
Funder
Universidad Nacional Autónoma de México
Reference53 articles.
1. GLOBOCAN (2023, December 14). GLOBOCAN 2020: New Global Cancer Data. Available online: https://www.uicc.org/news/globocan-2020-new-global-cancer-data.
2. Treatment of Metastatic Colorectal Cancer: ASCO Guideline;Morris;J. Clin. Oncol.,2022
3. An approach to p32/gC1qR/HABP1: A multifunctional protein with an essential role in cancer;Egusquiza;J. Cancer Res. Clin. Oncol.,2022
4. The C1q Receptors: Focus on gC1qR/p33 (C1qBP, p32, HABP-1);Ghebrehiwet;Semin. Inmunol.,2019
5. cC1qR/CR and gC1qR/p33: Observations in cancer;Peerschke;Mol. Immunol.,2014